The Hospitals
FDA moves spinal muscular atrophy screening tests to Class II
FDA kept special controls in place for the test system, but the new classification should make it easier for makers to bring to market. The order took effect June 11, 2026.
The Food and Drug Administration has moved spinal muscular atrophy newborn screening test systems into class II, the middle device tier. FDA says the change should keep safety checks in place while reducing the regulatory burden on a test meant to catch SMA early.
- FDA classified SMA newborn screening test systems as class II devices.
- Special controls still apply, including performance and labeling checks.
- The order took effect June 11, 2026.
- FDA says the change should reduce regulatory burdens and help access.
- The Food and Drug Administration, a federal agency, has put spinal muscular atrophy, or SMA, newborn screening test systems into class II, the middle device tier
The Food and Drug Administration, a federal agency, has put spinal muscular atrophy, or SMA, newborn screening test systems into class II, the middle device tier. The order took effect June 11, 2026, and it gives manufacturers a clearer path for a test meant to catch a serious condition early in life.
For families and the hospitals and labs that run newborn screening, the change matters because a device can move through review with less regulatory friction while still facing federal oversight. FDA said the classification should improve access to beneficial innovative devices and still provide a reasonable assurance of safety and effectiveness.
The guardrails stay on
The test system is a prescription device that looks for changes in the SMN1 gene using DNA from dried blood spot samples and polymerase chain reaction, or PCR. A presumptive positive result is only a starting point. It is meant to trigger confirmatory diagnostic testing, not replace it.
Class II does not mean a free pass. FDA said the device type will be subject to special controls tied to design verification and validation, labeling, performance studies, reproducibility, stability, and checks for false positives and false negatives. Those controls will be codified in 21 CFR part 866, and the device still falls under premarket notification, or 510(k), requirements unless FDA later exempts it.
Why the lower hurdle matters
Newborn screening works best when a condition can be spotted before symptoms take hold, because that gives families and doctors more time to act. A faster or easier route for a screening tool does not change the condition itself, but it can affect how quickly a test reaches hospitals, state labs and the babies they serve.
FDA said the classification was applicable on November 9, 2022, even though the order became effective this week. The practical result is a clearer rulebook for a test category that sits at the front end of care, where timing can matter as much as the diagnosis itself.